Venetoclax–Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview
Our real-world evidence shows that VR is an effective and well-tolerated option even after c-BTKi therapy in R/R CLL. These data complement evidence from emerging therapies and inform post-c-BTKi treatment selection in clinical practice.
Authors
- Panagiotis Tsaftaridis
- Alexia Piperidou (ORCID: https://orcid.org/0000-0002-3088-3938)
- Calliope Zerzi
- John Asimakopoulos (ORCID: https://orcid.org/0000-0003-1118-1700)
- Εliana Konstantinou
- Alexandros Machairas (ORCID: https://orcid.org/0000-0003-1856-3381)
- Panayiotis Panayiotidis (ORCID: https://orcid.org/0000-0003-0387-3993)
- Maria Dimou (ORCID: https://orcid.org/0000-0001-8197-9895)
- Rodanthi Fioretzaki (ORCID: https://orcid.org/0000-0003-1219-8715)
- Aikaterini Bitsani (ORCID: https://orcid.org/0000-0002-6711-4673)
- Παναγιώτα Πέτσα
- Marina Belia
- Aikaterini Benekou (ORCID: https://orcid.org/0000-0002-2135-6466)
- Theodoros P. Vassilakopoulos (ORCID: https://orcid.org/0000-0001-8766-1853)
- Marina P. Siakantaris (ORCID: https://orcid.org/0000-0002-3983-4657)
- Maria K. Angelopoulou (ORCID: https://orcid.org/0000-0002-1596-3630)
- Anastasia Kopsaftopoulou
- Fotios Panitsas (ORCID: https://orcid.org/0000-0002-3748-6142)
- Athanasios Liaskas
- Maria Arapaki
- Eleni Plata
Institutions
- National and Kapodistrian University of Athens (GR)
- Laiko General Hospital of Athens (GR)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3390/cancers17193159
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00